Academic Journal
Effects of Rituximab Including Long-term Maintenance Therapy in Children with Nephrotic Syndrome in a Single Center of Korea
| العنوان: | Effects of Rituximab Including Long-term Maintenance Therapy in Children with Nephrotic Syndrome in a Single Center of Korea |
|---|---|
| المؤلفون: | Seong Heon Kim, Taek Jin Lim, Ji Yeon Song, Su Young Kim |
| المصدر: | Childhood Kidney Diseases, Vol 22, Iss 1, Pp 1-6 (2018) |
| بيانات النشر: | Korean Society of Pediatric Nephrology, 2018. |
| سنة النشر: | 2018 |
| المجموعة: | LCC:Internal medicine LCC:Pediatrics |
| مصطلحات موضوعية: | nephrotic syndrome, children, rituximab, steroid-dependent, Internal medicine, RC31-1245, Pediatrics, RJ1-570 |
| الوصف: | Rituximab (RTX) is a chimeric monoclonal antibody that inhibits CD20-mediated B-cell proliferation and differentiation. Several studies have examined its use in intractable nephrotic syndrome (NS) with some positive results. However, those studies examined such effects for a short-term period of 1 year, and some patients continued to relapse after a lapse in RTX treatment. Our use of RTX as a maintenance therapy (RTX injection when the CD19 cell count exceeded 100–200/μL before relapse) showed some noticeable efficacy. We used RTX in 19 patients with steroid-dependent NS (SDNS). In 12 patients treated with RTX maintenance therapy, only one relapse occurred. The mean treatment period was 23.4±12.7 months, and the mean number of RTX administrations was 3.9±1.6. The relapse rates were decreased (from 2.68/year to 0.04/year), and the drug-free period also increased (from 22.5 days/year to 357.1 days/year) during maintenance therapy. The other seven patients were treated with one cycle of RTX or additional cycles in case of relapse (non-maintenance therapy). Relapse rates were significantly decreased after RTX treatment (from 1.76/year to 0.96/year, P=0.017). The relapse-free period was 15.55±7.38 (range, 5.3–30.7) months. No severe side effects of RTX were found except for a hypersensitivity reaction such as fever and chills during its infusion. In conclusion, RTX is considered an effective and safe option to reduce the relapse rate by a single- or maintenance-interval therapy in SDNS. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2384-0242 2384-0250 |
| Relation: | http://www.chikd.org/upload/ckd-22-1-1.pdf; https://doaj.org/toc/2384-0242; https://doaj.org/toc/2384-0250 |
| DOI: | 10.3339/jkspn.2018.22.1.1 |
| URL الوصول: | https://doaj.org/article/3e6bf48c5a314294a5099dcc8c23b37e |
| رقم الانضمام: | edsdoj.3e6bf48c5a314294a5099dcc8c23b37e |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 23840242 23840250 |
|---|---|
| DOI: | 10.3339/jkspn.2018.22.1.1 |